Supreme Court agrees to hear dispute over biologic drug sales

NEW YORK (Reuters) - The U.S. Supreme Court on Friday agreed to hear a dispute over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval to begin selling them.